×

Myriad Genetics to Present Three Clinical Studies on Prolaris(R) at the 2014 American Urological Association Annual Meeting

Myriad Genetics, Inc. Logo

SALT LAKE CITY, May 1, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced clinical data from three studies on Prolaris in prostate cancer patients will be featured at the 2014 American Urological Association (AUA) Annual Meeting, being held May 16–21, 2014, in Orlando, Fla. Prolaris is a novel molecular diagnostic test that accurately predicts cancer-specific death and metastases in men with prostate cancer and is a stronger indicator of clinical outcomes than Gleason score or PSA. In clinical practice, Prolaris is the only test to demonstrate that physicians changed their treatment plans in 65 percent of cases after receiving the test report – 40 percent of patients had a reduction in therapeutic burden, while 25 percent had an increase in therapeutic burden.

At the AUA annual meeting, new data will be presented from the largest clinical validation study to date of any gene-based prognostic test in patients with prostate cancer diagnosed from biopsy. In the second study to be presented, the data will show that the Prolaris test significantly outperformed the current procedure of upgrading to Gleason 3+4 or 4+3 in predicting biochemical recurrence after a radical prostatectomy. The third study will show the prognostic utility of Prolaris based on needle biopsy samples. These studies add to the growing body of outcomes data for Prolaris, which has been extensively validated in 11 clinical studies and more than 5,000 patients. Myriad also will present new data from an investigational diagnostic test for patients with renal cell carcinoma.

"More than ever, we are committed to developing novel molecular diagnostic tests to help to improve patient outcomes, survival and quality of life for people living with prostate and renal cancers," said Michael Brawer, M.D., vice president of Medical Affairs at Myriad. "Our Prolaris test is rapidly becoming the leading test to help the 240,000 men diagnosed with prostate cancer each year to determine if they have aggressive prostate cancer or not. We're also actively developing a new prognostic test for renal cell cancer, which affects 60,000 people every year."

2014 AUA – POSTER PRESENTATIONS
Title: Validation of a 46-gene cell cycle progression (CCP) RNA signature for predicting prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort.
Presenter: Jack Cuzick
Date: Tuesday, May 20, 3:30 p.m. to 5:30 p.m. EDT
Title: Cell Cycle Progression (CCP) outperforms upgrading to Gleason 3+4 or 4+3 in predicting biochemical recurrence after prostatectomy.
Presenter: Matthew Cooperberg
Date: Tuesday, May 20, 3:30 p.m. to 5:30 p.m. EDT
Title: Prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with prostatectomy.
Presenter: Jay Bishoff
Date: Tuesday, May 20, 3:30 p.m. to 5:30 p.m. EDT
Title: Cell cycle progression score predicts metastatic progression of clear cell renal cell carcinoma after resection.
Presenter: James Brown
Date: Sunday, May 18, 1:00 p.m. to 3:00 p.m. EDT

About Prolaris®

Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth. Low gene expression is associated with a low risk of disease progression in men who may be candidates for surveillance and high gene expression is associated with a higher risk of disease progression in patients who may benefit from additional therapy. Prolaris has been proven to predict prostate cancer-specific disease progression in 11 clinical trials with more than 5,000 patients. For more information visit: www.prolaris.com.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

Myriad, the Myriad logo, Prolaris, Myriad myPath, Myriad myPlan, and Myriad myRisk are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the presentation of Prolaris clinical study data at the 2014 AUA Annual Meeting; data showing that physicians would change their treatment plan of patients with prostate cancer based on Prolaris test results; the effectiveness of Prolaris testing to accurately predict cancer-specific disease progression and mortality when combined with clinical parameters such as Gleason score and PSA; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are management's present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and companion diagnostic services may decline or will not continue to increase at historical rates; risks related to changes in the governmental or private insurers reimbursement levels for our tests; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and companion diagnostic services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and companion diagnostic services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and companion diagnostic services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to increased competition and the development of new competing tests and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and companion diagnostic services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

CONTACT: Media Contact: Ron Rogers (801) 584-3065 rrogers@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com

Source:Myriad Genetics, Inc.